Planning for potential disruption in 2023 will be crucial for pharmaceutical companies that wish to mitigate supply chain woes further down the line. The situation regarding COVID-19 in China is already being hailed as a potential source of supply chain disruption, with some organisations…
Source: www.pmlive.com – Read more

News – Masimo reports cyber incident affecting production sites – teiss
Masimo has reported a cyber incident that has impacted its production sites. The company is currently assessing the situation to understand the extent of the